Title
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
Monthly Ranibizumab Versus Treat and Extend Ranibizumab for Diabetic Macular Edema
Phase
Phase 2Lead Sponsor
Retina Vitreous Associates of FloridaStudy Type
InterventionalStatus
Completed Results PostedIndication/Condition
Diabetic Retinopathy Macular EdemaIntervention/Treatment
ranibizumab ...Study Participants
20This study is to see whether treating diabetic retinal swelling with ranibizumab injections into the eye monthly is better than treating diabetic retinal swelling with ranibizumab injections into the eye less frequently.
This is a prospective randomized study comparing two groups of patients with diabetic macular edema. One group will receive injections of ranibizumab monthly and the other group will have the option to receive injections of ranibizumab less frequently. That is eligible to receive the injections less frequently will have fewer injections given if the patients in that group are doing well.
Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.
Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.
Patients randomized to the Monthly Ranibizumab arm of the study will be administered intravitreal injections each month for their diabetic macular edema for the duration of the study.
Patients randomized to this arm of the study will receive intravitreal injections of ranibizumab until their maculae are anatomically "dry," at which point the evaluation and injection interval will be extended.
Inclusion Criteria: Ability to provide written informed consent and comply with study assessments for the full duration of the study Age > 18 years Patient related considerations Phakic or pseudophakic patients with a known history of diabetes will be eligible. Women of reproductive age will be required to take a urine pregnancy test prior to administration of the study drug. Disease related considerations: Patients will have met standard, accepted diagnostic criteria for diabetes and will be currently treated with at least one systemic antihyperglycemic or insulin medication. Patients will have a BCVA ETDRS Snellen-equivalent less than or equal to 20/40 Central foveal thickness on SD-OCT of >300um Exclusion Criteria: Pregnancy (positive pregnancy test) or lactation Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch. Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated Participation in another simultaneous medical investigation or trial Foveal ischemia on IVFA Intraocular surgery less than 6 months ago Epiretinal membrane of clinical significance Prior vitrectomy Uncontrolled glaucoma Macular or peripheral laser within 90 Days from Day 0 injection Intravitreal steroid injection within 90 days from Day 0 injection Intravitreal or systemic anti-VEGF within 30 days from Day 0 injection
| Event Type | Organ System | Event Term | Monthly Ranibizumab | Treat and Extend Ranibizumab |
|---|
The ETDRS eye chart was used to assess vision at each visit, with the change through month 24 reported.
The average number of intravitreal ranibizumab injections in each arm of the study will be recorded.
Evaluate the average change in the swelling from diabetic macular edema measured with the optical coherence tomography machine.
The percentage of patients with 20/40 vision as assessed by the number of letters read correctly on the ETDRS eye chart at a starting test distance of 20 feet.
Spectral domain OCT will be used to check the patients' central foveal thickness at each visit and the percentage with "dry" maculas at months 3,6, and 12 based on spectral domain OCT measurements per the study protocol will be recorded.
